Diarrhea is a difficult diagnostic problem in patients with chronic graft-versus-host disease (cGVHD) because there are many causes of it. Although intestinal involvement has been reported in early studies of untreated cGVHD, this is now a very rare presentation of the disease. In addition to other etiologies, pancreatic insufficiency should also be considered in patients with cGVHD who demonstrate malabsorption. The pathogenesis of pancreatic insufficiency in these patients is unknown. Pancreatic enzyme supplements can be very effective in treating this rare condition. Bone Marrow Transplantation (2001) 27, 163-166. Keywords: chronic GVHD; malabsorption; diarrhea; pancreas; pancreatic insufficiency Although the incidence of diarrhea falls after day 100 following hematopoietic stem cell transplantation, it can still be a problem, particularly in patients with ongoing graftversus-host disease (GVHD).
Although the incidence of diarrhea falls after day 100 following hematopoietic stem cell transplantation, it can still be a problem, particularly in patients with ongoing graftversus-host disease (GVHD). 1, 2 The most common cause of diarrhea in long-term transplant survivors is infection because of the incomplete immune reconstitution in the majority of these patients, especially in those with cGVHD. [2] [3] [4] [5] [6] Although intestinal involvement in patients with untreated cGVHD was described in early studies, this is now a very rare phenomenon because of the widespread use of potent immunosuppressive(s) in the treatment of extensive cGVHD. The lower gastrointestinal (GI) tract, particularly the small bowel, is less frequently affected by cGVHD than the esophagus. The diagnosis of GI involvement by cGVHD requires extensive evaluation to rule out other causes of malabsorption or maldigestion. 5, 6 In this report, we present four cases with unexplained diarrhea masquerading as chronic gut GVHD. 
Case reports

Case one
A 38-year-old white male with chronic myelogeneous leukemia in chronic phase underwent allogeneic bone marrow transplantation (BMT) from his HLA-identical sibling following a busulfan/cyclophosphamide conditioning regimen. His past history was significant for abdominal trauma due to a motor vehicle accident. Approximately 3 months after his BMT, the patient developed a skin rash, oral lichenoid changes and dry eye symptoms, which were consistent with chronic GVHD. A skin biopsy was inconclusive but a salivary gland biopsy confirmed the diagnosis of cGVHD. He responded to an immunosuppressive regimen which included steroids, cyclosporine and PUVA.
At the 6 month follow-up visit, he was noted to have abdominal discomfort, bloating and nausea, which did not improve with an H-2 receptor blocker, omeprazole, propulsid or ondansetron. An esophagogastroduedenoscopy (EGD) was unremarkable. Gastric and duodenal biopsies were negative for GVHD and any infectious agents. Subsequently, his cGVHD flared with increased oral symptoms associated with lichenoid lesions, skin rash and abnormal liver function tests. Thalidomide was added to cyclosporine and prednisone. Although his cGVHD improved with this therapy, the GI symptoms persisted. At 20 months post BMT, he developed upper abdominal pain and diarrhea. His diarrhea was liquid, foul smelling and had an oily appearance. It was initially felt to be antibiotic-associated because of positive stool C. difficile toxin. He was put on metronidazole but the diarrhea persisted despite a prolonged course of therapy, and he lost 12 lbs within a few months. C. difficile was negative on repeat examinations. Because of persistent diarrhea and abdominal cramping he was evaluated by a gastroenterologist and was felt to have malabsorption. Upper and lower GI endoscopies and extensive workup for infectious causes were again negative. Duodenal biopsies showed mild fibrosis and focally prominent eosinophils. Gastric biopsies revealed possible mild gastritis. No viral inclusions, fungi or other microorganisms were seen. A D-xylose absorption test was negative. At the time of this evaluation he had progression of cGVHD with sclerodermatous changes on his face and was treated with tacrolimus and mycophenolic acid. A CT scan of the abdomen was remarkable for the appearance of an atrophic pancreas, raising the diagnosis of chronic pancreatitis. He was treated with a pancreatic enzyme supplement (Creon-20, Solvay Pharmaceuticals, Marietta, GA, USA) and omeprazole. The diarrhea and abdominal symptoms remitted within 2 weeks after the initiation of pancreatic enzyme replacement. The diarrhea did not recur and he remained on a tapering schedule of immunosuppressive agents while receiving a maintenance dose of pancreatic enzyme replacement for 6 months.
Case two
A 2-year-old male with juvenile CML was diagnosed at 2 months of age and treated with daunorubicin, etoposide, cytosine arabinoside (Ara-C), 6-thioguanine, dexamethasone and intrathecal Ara-C. He underwent allogeneic BMT from his HLA-identical sister following a TBI-containing conditioning regimen, without significant complications. He received cyclosporine for GVHD prophylaxis. Approximately 3 months after his BMT, he developed a skin rash consistent with GVHD. He was started on steroids that were slowly tapered over 5 months. Three months after the discontinuation of steroid, he had a new skin rash diagnosed as chronic GVHD. Azathioprine was added to his cyclosporine treatment. At 16 months post transplant, all immunosuppression was discontinued after a slow taper. One month later, he was noted to have sclerodermatous changes of his flanks and hands. The dose of immunosuppression was increased and etretinate was added. He had chronic diarrhea which led him to undergo an extensive GI evaluation including serum amylase, a D-xylose absorption test, 24-hour fecal fat quantification, upper GI series, EGD, and colonoscopy which were all unrevealing. There was no evidence of infection GVHD involvement of the GI tract. He was started on nasogastric feeding because of excessive weight lost. He was treated with flucanozole for the positive Candida albicans in his stool culture. At 22 months post BMT, his diarrhea became voluminous and malodorous. He underwent another EGD and biopsy which were normal with no evidence of GVHD. He was subsequently put on empiric pancreatic enzyme replacement therapy (Pancrease, McNeil, Raritan, NJ, USA) with oral nutritional supplement (Pediasure, Ross, Columbus, OH, USA). On this regimen, his GI symptoms resolved with a marked decrease in the diarrhea. He remained free of GI symptoms during his further follow-up of 7 years.
Case three
A 4-year-old girl with acute lymphoblastic leukemia underwent an allogeneic bone marrow transplant from her HLA-matched sister following cyclophosphamide and total body irradiation. The patient initially did well but relapsed shortly after transplant. She was successfully reinduced into a third CR and subsequently had a second allogeneic BMT following a preparative regimen of busulfan, cyclophosphamide and etoposide. She was not given any GVHD prophylaxis after the second BMT. Two months later, she developed progressive onset of chronic GVHD of skin and liver and was treated with a steroid to which she responded initially. However, her GVHD progressed while she was receiving prednisone and azathioprine. She developed a generalized skin rash, oral lichenoid lesions and significant elevation of alkaline phosphatase suggesting liver involvement. She was placed on thalidomide in addition to steroid. Approximately 8 months after the initial diagnosis of cGVHD, the mother noted that the patient was having two or three daily bowel movements that had an orange, greasy appearance and floated in the toilet bowl. Most of these stools were described as small, but some of them were large and bulky. Her stool pattern remained unchanged during subsequent follow-up. There was no fever or other signs of infection. Parasitology studies were negative. An extensive GI evaluation including upper GI series and endoscopies were normal. There was no evidence of cGVHD in biopsy specimens. D-xylose absorption test was also normal. The 24-h fecal fat study demonstrated significant fat excretion. In view of the history, physical findings and stool examination, her GI symptoms were felt most likely to be secondary to malabsorption/maldigestion. She was started on pancreatic enzyme replacement (Pancrease) which resulted in significant improvement in her symptoms. The patient ultimately died of relapse of leukemia.
Case four
A 25-year-old white female with acute myelogenous leukaemia in second remission underwent allogeneic BMT from her HLA-identical sibling following a cyclophosphamide and TBI conditioning regimen. On day 12 post BMT, she developed stage II acute GVHD involving skin, liver and GI tract. She also developed abdominal distention, hypotension, weight gain and non-cardiogenic pulmonary edema which were consistent with capillary leak syndrome. She was treated with high-dose parenteral methylprednisolone and diuretics. She required elective intubation and mechanical ventilation during this period. Her hospital course was also complicated by pneumonia and several episodes of GI bleeding. Her GVHD responded to a high-dose steroid with significant improvement in the skin rash and stabilization of liver function. Her respiratory status also improved and she was extubated. However, she continued to have a moderate amount of diarrhea with a negative work-up for any infectious etiology. Abdominal ultrasound showed a normal gallbladder, common bile duct and pancreas.
On day 92, the patient had a new rash superimposed on chronic erythema, hyperpigmentation and scaling consistent with chronic GVHD. She had significant dryness and pruritus. A repeat skin biopsy revealed both acute and chronic GVHD. She was placed on high-dose parenteral steroid, the skin rash resolved and liver function tests improved significantly. However, her diarrhea persisted and became more voluminous (greater than 1 l/day) despite the use of anti-diarrheal agents. The stool was liquid, dark brown and foul smelling. No abdominal cramping was noted. Her steroid continued to be tapered. On day 121 post BMT, she was reevaluated because of persistent diarrhea. Results showed grossly abnormal amounts of fecal fat (14.4 g/24 h with a normal value of Ͻ6 g) and normal D-xylose absorption test and serum amylase level. Clostridium difficile, ova and parasites and all other surveillance cultures were negative. Based on these results, the patient was begun on exocrine pancreatic enzyme replacement (Cotazym, Organon, West Orange, NJ, USA) therapy with meals. She responded to therapy with complete resolution of her diarrhea after escalating the dose of pancreatic enzyme replacement. She remained on this therapy for about 4 months which was then tapered off.
Discussion
In clinical practice, physicians are often faced with patients with cGVHD who have a variety of GI symptoms such as esophageal reflux, dysphagia, bloating, weight loss, and diarrhea. 5, 7 The possible causes of diarrhea occurring after hematopoietic stem cell transplantation are outlined in Table 1 . Patients with severe cGVHD may also present with wasting or failure to thrive, which may improve with effective immunosuppressive therapy. 8, 9 We describe four cases with a common clinical presentation of malabsorption secondary to pancreatic insufficiency. In all cases, the symptoms were initially felt to be due to gut GVHD because of the absence of infectious causes and the presence of cGVHD. However, comprehensive evaluations of the GI tract including radiologic and endoscopic studies did not show evidence of GVHD. All biopsy specimens were negative. It should be noted, however, that the histopathologic diagnosis of chronic gut GVHD may be difficult to make with muscosal biopsies because fibrosis and other histologic findings including mononuclear cell infiltration and sclerosis and hyalinization of small venules are usually confined to the submucosa and subserosa. 9 After infection and gut GVHD have been excluded, the cause of diarrhea seen in these four patients was considered to be either due to an unidentified small bowel mucosal etiology or pancreatic insufficiency potentially from chronic pancreatitis. The likelihood of pancreatitis was of particular importance in the first case because of a previous history of abdominal trauma and atrophic pancreas on the CT scan. Three of the patients had received a total body irradiation-containing preparative regimen which can also be complicated by pancreatitis.
Diarrhea secondary to pancreatic insufficiency was previously described in two separate cases after allogeneic bone marrow transplantation. 10, 11 The first case was a 7-year-old boy with beta thalassemia who developed abdominal pain and profuse pale and offensive diarrhea on day 48 Table 1 Common causes of diarrhea after BMT
Ͻ6 months
Toxicity from the conditioning regimen (the earliest) Acute graft-versus-host disease (the most common) Enteric infections Fat and carbohydrate malabsorption Medications that cause diarrhea
Ͼ6 months Enteric infections (the most common)
Intestinal involvement with chronic GVHD (now, very rare) Secretory Ig A deficiency associated with cGVHD Pancreatic insufficiency (possible) post transplant when he had ongoing skin, gut and hepatic GVHD. Although pancreatic enzyme levels after secretion stimulation were found to be low in this patient, the exact etiology of the diarrhea remained unclear because all GVHD symptoms and findings, including the diarrhea, remitted after intravenous methylprednisolone was started in very close conjunction with pancreatic enzyme supplements. 10 The value of measuring serum pancreatic enzyme levels in the diagnosis of pancreatitis is controversial, particularly during the early course of transplant. Tyden et al 12 suggested that all patients have a more or less pronounced pancreatic insufficiency during the first months following conditioning therapy (cyclophosphamide and total body irradiation) and subsequent BMT. They also found no correlation between the severity of acute GVHD and depression of pancreatic amylase. The other case was a 40-year-old woman with multiple myeloma who developed severe diarrhea with weight loss highly suggestive of malabsorption, 10 months after an allogeneic BMT from a matched-sibling donor. At about that time cGVHD of the liver was also diagnosed clinically and treated with a 2 month course of azathioprine. Pancreolauryl test was consistent with pancreatic insufficiency. She was subsequently given pancreatic enzyme supplements together with cimetidine. This regimen abolished the diarrhea over the next 3 months and led to weight gain. It was assumed that pancreatic insufficiency resulted from either GVHD or drugs. 11 In view of these reports and our case series, it is highly possible that pancreatic insufficiency may develop in some long-term transplant survivors. The presentation of steatorrhea, foul-smelling stools, and weight loss despite adequate caloric intake is typical. The pathogenesis is currently subject to speculation, but in view of the frequent finding of acute pancreatitis at autopsy after transplantation, the most likely cause is pancreatic atrophy as a result of previous pancreatic damage. 13 Pancreatic insufficiency after BMT may also be a feature of GVHD. Autopsy evidence of GVHD has been found in the pancreas 14 and similar changes have been seen in experimental models of GVHD. 15 Azathioprine, cyclosporine, glucocorticoids and l-asparaginase are reported to have a strong association with pancreatitis. 16, 17 It is possible that the etiology of pancreatic insufficiency in these patients is drug-induced pancreatitis.
In cGVHD patients who present with malabsorption or maldigestion, one is faced with the dilemma of either testing small bowel and pancreatic functions first or proceeding with a trial of pancreatic enzyme therapy. The D-xylose absorption test is currently considered to be a good screening test of intestinal function. It helps to separate patients with small bowel dysfunction from those with pancreatic insufficiency. CT scan of the pancreas may also be helpful as it was in our first case. In another report, CT showed complete absence of pancreatic tissue in a patient who developed pancreatic insufficiency 4 years after transplantation. 2 A variety of tests are available to assess pancreatic function and to diagnose pancreatic insufficiency, 18, 19 but are generally underused because of technical difficulties, problems with patient compliance, perceived inaccuracies, 12 or unfamiliarity with the testing methods. 20 Furthermore, the assessment of patients with cGVHD can be more difficult because of their functional and emotional limitations. Therefore, taking a good history is extremely important in the diagnosis by limiting possibilities and unnecessary examinations. Although we evaluated our patients to a variable extent before initiating pancreatic enzyme replacement, we did not particularly study pancreatic function because of all these concerns. All four patients had dramatic responses to the replacement therapy with resolution of their GI symptoms. It should be noted that dose escalation might be necessary to obtain the optimum response to enzyme replacement, as we noted in the fourth patient. Once the response is achieved, the dose and duration of enzyme replacement therapy can be adjusted accordingly.
Based on these observations, we recommend performing a few screening studies, including serum amylase, fecal fat excretion, D-xylose absorption test, and a CT scan of the upper abdomen to evaluate malabsorption before initiating replacement therapy. An empiric trial of pancreatic enzyme supplement and follow-up of the clinical response is the most logical management approach in this group of patients if fat malabsorption is suggested by history and screening studies.
